Antibody Recruiting Molecules (ARMs) are bispecific molecules that recruit endogenous antibodies to target cancer, virally infected cells, and disease-causing microorganisms for immune destruction. They are comprised of two distinct binding domains connected by a tunable linker domain. One binding domain attaches to circulating antibodies and the other attaches to disease cells. These molecules are engineered with modular components that are readily interchangeable, giving the platform tremendous flexibility to target a variety of disease cells and tumor types.
HOW ARMS WORK
The ARM's target-binding domain binds tightly to specific molecules expressed on the disease cell's surface. Its antibody-binding domain attaches to antibodies already present in the patient's body and the micro-environment of the disease cells. By creating this “bridge”, ARMs enable endogenous antibodies to coat the cell, leading to the destruction of the disease cell through the body’s innate antibody-mediated immune mechanisms.
Similar to biologics, ARMs directly engage patients’ immune system to destroy disease cells by connecting target cancer cells with components of the immune system. However, compared to biologics, ARMs offer many advantages. ARMs are smaller and more tunable allowing for more versatility. They have the potential to be safer and more effective because they are non-immunogenic and can attach to a wider range of binding sites on disease cells. Finally, our fully synthetic and modular design, makes their production much faster and less costly.